Iyoda, Masayuki and Hudkins, Kelly L. and Becker-Herman, Shirly and Wietecha, Tomasz A. and Banas, Miriam C. and Guo, Shunhua and Meyer-Bahlburg, Almut and Kowalewska, Jolanta and Liu, Gang and Ziegler, Steven F. and Rawlings, David J. and Alpers, Charles E. (2009) Imatinib Suppresses Cryoglobulinemia and Secondary Membranoproliferative Glomerulonephritis. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 20 (1). pp. 68-77. ISSN 1046-6673, 1533-3450
Full text not available from this repository. (Request a copy)Abstract
Imatinib is a receptor tyrosine kinase inhibitor that blocks the activity of c-Abl, c-Kit, and PDGF receptors. We tested the protective effects of imatinib in thymic stromal lymphopoietin transgenic mice, a model of cryoglobulinemia and associated membranoproliferative glomerulonephritis (MPGN), in which some glomerular manifestations likely result from PDGF receptor activation. Surprising, administration of imatinib beginning at weaning suppressed production of cryoglobulin, attenuating both the renal injury and systemic features of cryoglobulinemia. Flow cytometry suggested that inhibition of B cell development in the bone marrow likely caused the reduction in cryoglobulin production. In addition, administration of imatinib to thymic stromal lymphopoietin transgenic mice with established MPGN also diminished cryoglobulin production and reversed the renal and systemic lesions. These data suggest that treatment with imatinib may be a novel therapeutic approach for cryoglobulinemia and MPGN in humans.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | THYMIC STROMAL LYMPHOPOIETIN; B-CELL DEVELOPMENT; ABL-DEFICIENT MICE; GROWTH-FACTOR; TRANSGENIC MICE; IN-VITRO; RENAL-DISEASE; BONE-MARROW; PDGF-D; C-KIT; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Nephrologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Oct 2020 07:34 |
| Last Modified: | 13 Oct 2020 07:34 |
| URI: | https://pred.uni-regensburg.de/id/eprint/29795 |
Actions (login required)
 |
View Item |
